Singapore, April 10 -- Cartherics, an Australia-based biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, have announced an enhanced partnership.

The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialisation of Cartherics' iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics' mission to develop immune cell therapy pr...